Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: hydrogen sulfide-based therapeutics - Antibe Therapeutics

Drug Profile

Research programme: hydrogen sulfide-based therapeutics - Antibe Therapeutics

Alternative Names: Aspirin derivative - Antibe Therapeutics; ATB 340; ATB-282; ATB-284; ATB-352; ATB-427; ATB-428; ATB-429

Latest Information Update: 28 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Antibe Therapeutics
  • Class Analgesics; Anti-inflammatories; Anticoagulants; Sulfides
  • Mechanism of Action Cyclooxygenase inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute pain; Blood coagulation disorders
  • No development reported Inflammatory bowel diseases; Irritable bowel syndrome

Most Recent Events

  • 26 Feb 2018 Hydrogen sulfide based ATB 352 is still in preclinical development for Acute pain in Canada
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Acute pain in Canada
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top